These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 26367811)
1. Vaccine Failure After Meningococcal C Conjugate Vaccine May Be Linked to Decline of Bactericidal Titers and Absence of Herd Immunity. Matar R; Hong E; Levy C; Guillot M; Cohen R; Taha MK; Madhi F Pediatr Infect Dis J; 2015 Oct; 34(10):1142-3. PubMed ID: 26367811 [No Abstract] [Full Text] [Related]
2. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England. Ladhani SN; Giuliani MM; Biolchi A; Pizza M; Beebeejaun K; Lucidarme J; Findlow J; Ramsay ME; Borrow R Emerg Infect Dis; 2016 Feb; 22(2):309-11. PubMed ID: 26811872 [TBL] [Abstract][Full Text] [Related]
3. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination. Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078 [TBL] [Abstract][Full Text] [Related]
4. Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C®) in infants. Poellabauer EM; Pavlova BG; Fritsch S; Singer J; Neubauer C; Doralt J; Valenta-Singer B; Ehrlich HJ Vaccine; 2013 Aug; 31(35):3611-6. PubMed ID: 23672977 [TBL] [Abstract][Full Text] [Related]
5. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725 [TBL] [Abstract][Full Text] [Related]
6. Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom. Ramasamy MN; Clutterbuck EA; Haworth K; Bowman J; Omar O; Thompson AJ; Blanchard-Rohner G; Yu LM; Snape MD; Pollard AJ Clin Vaccine Immunol; 2014 Aug; 21(8):1164-8. PubMed ID: 24964805 [TBL] [Abstract][Full Text] [Related]
7. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients. Wyplosz B; Derradji O; Hong E; François H; Durrbach A; Duclos-Vallée JC; Samuel D; Escaut L; Launay O; Vittecoq D; Taha MK Transpl Infect Dis; 2015 Apr; 17(2):322-7. PubMed ID: 25645691 [TBL] [Abstract][Full Text] [Related]
8. A vaccine against meningitis in Africa. Lancet Infect Dis; 2011 Jan; 11(1):1. PubMed ID: 21183138 [No Abstract] [Full Text] [Related]
9. Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines. Heyderman RS; Davenport V; Williams NA Trends Microbiol; 2006 Mar; 14(3):120-4. PubMed ID: 16469496 [TBL] [Abstract][Full Text] [Related]
10. Toward a meningitis-free world. Black S; Pizza M; Nissum M; Rappuoli R Sci Transl Med; 2012 Feb; 4(123):123ps5. PubMed ID: 22378923 [TBL] [Abstract][Full Text] [Related]
11. Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins. Bielecka MK; Devos N; Gilbert M; Hung MC; Weynants V; Heckels JE; Christodoulides M Infect Immun; 2015 Feb; 83(2):730-42. PubMed ID: 25452551 [TBL] [Abstract][Full Text] [Related]
12. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine. El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952 [TBL] [Abstract][Full Text] [Related]